公开(公告)号：US12163149B2

公开(公告)日：2024-12-10

申请号：US18147156

申请日：2022-12-28

Applicant: TOOLGEN INCORPORATED

Inventor： Seokjoong Kim ,  Dong Woo Song ,  Jae Young Lee ,  Jung Min Lee ,  Gyu-bon Cho ,  Hee Sook Bae

IPC: C07H21/02 ,  C12N9/22 ,  C12N15/113 ,  C12N15/85

Abstract: The present invention relates to an expression control composition for controlling the expression of a duplicate gene or a method using the same. In addition, the present invention relates to a method of treating or improving a disease caused by gene duplication using the expression control composition for controlling the expression of a duplicate gene.

公开(公告)号：US20150284727A1

公开(公告)日：2015-10-08

申请号：US14438098

申请日：2013-10-23

Applicant: TOOLGEN INCORPORATED

Inventor： Jin-Soo Kim ,  Seung Woo Cho ,  Sojung Kim ,  Jong Min Kim ,  Seokjoong Kim

IPC: C12N15/52 ,  C12N9/16

CPC classification number: C12N15/52 ,  C12N9/16 ,  C12N9/22 ,  C12N15/102 ,  C12N15/111 ,  C12N15/63 ,  C12N15/8216 ,  C12N15/85 ,  C12N15/907 ,  C12N2310/10 ,  C12N2310/20 ,  C12N2310/531 ,  C12Y301/21

Abstract: The present invention relates to targeted genome editing in eukaryotic cells or organisms. More particularly, the present invention relates to a composition for cleaving a target DNA in eukaryotic cells or organisms comprising a guide RNA specific for the target DNA and Cas protein-encoding nucleic acid or Cas protein, and use thereof.

Abstract translation: 本发明涉及真核细胞或生物体中靶向的基因组编辑。 更具体地说，本发明涉及用于在真核细胞或生物体中切割靶DNA的组合物，其包含对靶DNA和Cas蛋白质编码核酸或Cas蛋白质特异性的引导RNA及其用途。

公开(公告)号：US11999952B2

公开(公告)日：2024-06-04

申请号：US17236660

申请日：2021-04-21

Applicant: TOOLGEN INCORPORATED ,  SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION ,  SEOUL NATIONAL UNIVERSITY HOSPITAL

Inventor： Jeong Hun Kim ,  Sung Wook Park ,  Seokjoong Kim ,  Dong Woo Song

IPC: C12N15/00 ,  A61K9/00 ,  A61K38/46 ,  A61K48/00 ,  C07K14/47 ,  C07K14/515 ,  C07K14/52 ,  C12N9/22 ,  C12N15/11 ,  C12N15/113 ,  C12N15/86

CPC classification number: C12N15/11 ,  A61K9/0048 ,  A61K38/465 ,  A61K48/00 ,  A61K48/005 ,  C07K14/4702 ,  C07K14/515 ,  C07K14/52 ,  C12N9/22 ,  C12N15/113 ,  C12N15/1136 ,  C12N15/86 ,  A01K2227/105 ,  A01K2267/03 ,  C12N2310/20 ,  C12N2750/14143 ,  Y02A50/30

Abstract: The present invention relates to an artificially manipulated neovascularization-associated factor for regulating neovascularization and a use thereof. More particularly, the present invention relates to a system for artificially regulating neovascularization, which includes an artificially manipulated neovascularization-associated factor for regulating neovascularization and/or a composition for artificially manipulating the neovascularization-associated factor. In a specific aspect, a neovascularization regulatory system including a neovascularization-associated factor such as artificially manipulated VEGFA, HIF1A, ANGPT2, EPAS1, or ANGPTL4 and/or an expression product thereof is provided.

公开(公告)号：US11441135B2

公开(公告)日：2022-09-13

申请号：US16628199

申请日：2018-07-06

Applicant: TOOLGEN INCORPORATED

Inventor： Young-Hoon Kim ,  Min Hee Jung ,  Joonsun Lee ,  Eunji Shin ,  Kang In Lee ,  Seokjoong Kim ,  Jeongjoon Lee

IPC: C12N9/22 ,  C12N9/78 ,  C12N15/86

Abstract: The present invention relates to an artificially engineered CRISPR/Cas9 system. More particularly, the present invention relates to an artificially engineered CRISPR enzyme having enhanced target specificity and a use of an artificially engineered CRISPR/Cas9 system including the same enzyme in genome and/or epigenome manipulation or modification, genome targeting, genome editing, and in vitro diagnosis, etc.

公开(公告)号：US11667934B2

公开(公告)日：2023-06-06

申请号：US16623017

申请日：2018-06-15

Applicant: TOOLGEN INCORPORATED

Inventor： Seokjoong Kim ,  Dong Woo Song ,  Kyu Jun Lee ,  Jung-Min Lee ,  Un-Gi Kim

IPC: C12N15/90 ,  C12N9/22 ,  C12N9/64 ,  C12N15/11 ,  C12N15/86 ,  A61K38/17 ,  A61P7/04 ,  A61K48/00 ,  C07K14/775 ,  C12N15/113

CPC classification number: C12N15/907 ,  C12N9/22 ,  C12N9/644 ,  C12N15/11 ,  C12N15/86 ,  C12N2310/20 ,  C12N2750/14143 ,  C12N2800/80

Abstract: Provided is a platform for expressing a protein of interest by artificially manipulating the liver, and more particularly, to a platform for alleviating or treating a genetic disorder or improving a body function by inducing expression by inserting a transgene (e.g., a therapeutic gene) which can function or be expressed normally, into a high-expression secretory gene, instead of a disease gene which functions or is expressed abnormally. The high-expression secretory gene includes the HP or APOC3 gene. The transgene includes one that is highly expressed using a promoter in a hepatocyte genome and is secretory out of the cell.

公开(公告)号：US11572574B2

公开(公告)日：2023-02-07

申请号：US16776707

申请日：2020-01-30

Applicant: TOOLGEN INCORPORATED

Inventor： Seokjoong Kim ,  Dong Woo Song ,  Jae Young Lee ,  Jung Min Lee ,  Gyu-bon Cho ,  Hee Sook Bae

IPC: C07H21/02 ,  C07H21/04 ,  C12N15/85 ,  C12N15/113 ,  C12N9/22

Abstract: The present invention relates to an expression control composition for controlling the expression of a duplicate gene or a method using the same. In addition, the present invention relates to a method of treating or improving a disease caused by gene duplication using the expression control composition for controlling the expression of a duplicate gene.